Literature DB >> 874077

Big and little forms of osteoclast activating factor.

G R Mundy, L G Raisz, J L Shapiro, J G Bandelin, R J Turcotte.   

Abstract

We have further characterized osteoclast activating factor (OAF) using a bioassay for bone resorption which utilizes the release of previously incorporated (45)Ca from fetal rat long bones in organ culture. When supernatant media from activated leukocyte cultures were concentrated on Amicon PM10 membranes (assigned molecular weight cutoff 10,000 daltons) and chromatographed on Sephadex G-50 columns, the bone-resorbing activity eluted between the molecular weight markers chymotrypsinogen (25,000 daltons) and cytochrome c (12,500 daltons). This peak of biological activity has been called big OAF. When filtrates from the PM10 membranes were concentrated on Amicon UM2 membranes (assigned molecular weight cutoff 1,000 daltons) and chromatographed on Sephadex G-50 columns, some of the biological activity eluted between the molecular weight markers chymotrypsinogen and cytochrome c (big OAF), but there was a separate peak of biological activity which eluted with [(3)H]proline (140 daltons). This second peak has been called little OAF. Little OAF was eluted from Bio-Gel P6 columns between the molecular weight markers calcitonin (approximately 3,500 daltons) and vitamin B(12) (1,330 daltons), but was retained by Spectrapor dialysis tubing (nominal molecular weight cutoff 3,500 daltons). Big OAF was converted to little OAF by equilibration in 1 M NaCl or 2 M urea. Little OAF was self-associated back to big OAF by equilibration in buffers of low ionic strength (Tris-HCl 10-50 mM). Little OAF was extracted into the organic phase in ethyl acetate after acidification of the sample to pH 3.5. The biological activity remained in the aqueous phase after ethyl acetate extraction at pH 7.5-8.4. Little OAF has been purified more than 6,000-fold compared with the original material so that bone-resorbing activity is maximal in a sample with a protein concentration of 80 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874077      PMCID: PMC372350          DOI: 10.1172/JCI108748

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  BONE RESORPTION IN TISSUE CULTURE. FACTORS INFLUENCING THE RESPONSE TO PARATHYROID HORMONE.

Authors:  L G RAISZ
Journal:  J Clin Invest       Date:  1965-01       Impact factor: 14.808

2.  Growth of embryonic avian and mammalian tibiae on a relatively simple chemically defined medium.

Authors:  J D BIGGERS; R B GWATKIN; S HEYNER
Journal:  Exp Cell Res       Date:  1961-10       Impact factor: 3.905

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 4.  Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators.

Authors:  J R David; R R David
Journal:  Prog Allergy       Date:  1972

5.  Evidence for the secretion of an osteoclast stimulating factor in myeloma.

Authors:  G R Mundy; L G Raisz; R A Cooper; G P Schechter; S E Salmon
Journal:  N Engl J Med       Date:  1974-11-14       Impact factor: 91.245

6.  Bone-resorbing activity in supernatants from lymphoid cell lines.

Authors:  G R Mundy; R A Luben; L G Raisz; J J Oppenheim; D N Buell
Journal:  N Engl J Med       Date:  1974-04-18       Impact factor: 91.245

7.  Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes.

Authors:  J E Horton; L G Raisz; H A Simmons; J J Oppenheim; S E Mergenhagen
Journal:  Science       Date:  1972-09-01       Impact factor: 47.728

8.  Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytes.

Authors:  R E Rocklin; H G Remold; J R David
Journal:  Cell Immunol       Date:  1972-11       Impact factor: 4.868

9.  Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.

Authors:  R A Luben; G R Mundy; C L Trummel; L G Raisz
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  A sensitive method for the assay of 5-hydroxytryptamine.

Authors:  J R VANE
Journal:  Br J Pharmacol Chemother       Date:  1957-09
View more
  8 in total

1.  Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.

Authors:  H A Kulenkampff; T Dreyer; W Kersjes; G Delling
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism.

Authors:  E Abe; C Miyaura; H Tanaka; Y Shiina; T Kuribayashi; S Suda; Y Nishii; H F DeLuca; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

Review 3.  Hypercalcemia and cancer: an update.

Authors:  T M Murray; R G Josse; J N Heersche
Journal:  Can Med Assoc J       Date:  1978-10-21       Impact factor: 8.262

4.  Thymus-derived lymphocytes and their interactions with macrophages are required for the production of osteoclast-activating factor in the mouse.

Authors:  M Horowitz; A Vignery; R K Gershon; R Baron
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

5.  Release of the lymphokine osteoclast activating factor requires cyclic AMP accumulation.

Authors:  T Yoneda; G R Mundy
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

6.  Ultrastructural evaluation of adenocarcinomas derived from apocrine glands of the anal sac associated with hypercalcemia in dogs.

Authors:  D J Meuten; C C Capen; G J Kociba; D J Chew; B J Cooper
Journal:  Am J Pathol       Date:  1982-05       Impact factor: 4.307

7.  Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.

Authors:  R G Josse; T M Murray; G R Mundy; D Jez; J N Heersche
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

8.  Lymphokine-mediated bone resorption requires endogenous prostaglandin synthesis.

Authors:  R S Bockman; M A Repo
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.